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Key Points
• Sickle cell disease,
a-thalassemia trait,
and G6PD deficiency
are common among
Malawian children ,5
years of age.
• These inherited blood
disorders likely contrib-
ute to the severity
of both anemia
and malaria.
In sub-Saharan Africa, inherited causes of anemia are common, but data are limited
regarding the geographical prevalence and coinheritance of these conditions and their
overall contributions to childhood anemia. To address these questions in Malawi, we
performed a secondary analysis of the 2015-2016MalawiMicronutrient Survey, a nationally
and regionally representative survey that estimated the prevalence of micronutrient
deﬁciencies and evaluated both inherited and noninherited determinants of anemia.
Children age 6 to 59 months were sampled from 105 clusters within the 2015-2016 Malawi
Demographic Health Survey. Hemoglobin, ferritin, retinol binding protein, malaria, and
inﬂammatory biomarkers were measured from venous blood. Molecular studies were
performed using dried blood spots to determine the presence of sickle cell disease or trait,
a-thalassemia trait, and glucose-6-phosphate dehydrogenase (G6PD) deﬁciency. Of 1279
eligible children, 1071 were included in the ﬁnal analysis. Anemia, iron deﬁciency, and
malaria were common, affecting 30.9%, 21.5%, and 27.8% of the participating children,
respectively. a-Thalassemia trait was common (.40% of children demonstrating deletion
of 1 [33.1%] or 2 [10.0%] a-globin genes) and associated with higher prevalence of anemia
(P , .001). Approximately 20% of males had G6PD deﬁciency, which was associated with a
1.0 g/dL protection in hemoglobin decline during malaria infection (P 5 .02). These data
document that inherited blood disorders are common and likely play an important role
in the prevalence of anemia and malaria in Malawian children.
Introduction
Inherited hematological disorders are highly prevalent across Africa, primarily because of the tremendous
selective pressure frommalaria-causingPlasmodium parasites.1-4 Following the initial hypothesis by Haldane,5
the protective effect of various inherited hematological polymorphisms and mutations against severe malaria
have been characterized, including hemoglobin sickle (HbS),6-10 HbC,11,12 HbE,13-15 both a-16-18 and
b-thalassemia,19-22 and glucose-6-phosphate dehydrogenase (G6PD) deficiency.23-25 In the hetero-
zygous carrier state (trait), these genetic changes are beneficial, providing protection against the deadly
consequences of severe malaria. However, in the homozygous disease state, these conditions result in a
wide spectrum of laboratory and clinical sequelae, including severe anemia and early mortality.26-28
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The geographical distribution of inherited blood disorders across
sub-Saharan Africa is well-recognized,29-32 but the prevalence and
distribution within individual countries is much less appreciated,
limited by poor availability of published data. In contrast, the
burden of anemia in Africa and the associatedmorbidity andmortality is
well-described.33,34 Although nutritional deficiencies and infections
(malaria, HIV, and parasitic infections) are considered the most
common global causes of anemia,35-40 the contribution of inherited
blood disorders to the burden of anemia in the malaria-endemic
regions of sub-Saharan Africa has not been extensively described at
the national level, particularly in Malawi.41-45
A widely referenced study fromMalawi demonstrated themultifactorial
etiology of severe anemia in children, including malaria, hookworm,
HIV, G6PD deficiency, and several nutritional deficiencies.44 Perhaps
because of its geographical position in southeastern Africa, Malawi is
often overlooked as a country with a high burden of sickle cell anemia
and other inherited blood disorders, but given the endemicity of
malaria, we hypothesized that there is likely a high frequency of
inherited hematological disorders that have evolved because of their
relative protection against severe malaria, including the HbS mutation,
a-globin gene deletions, and G6PD deficiency. In conjunction with
the 2015-2016 Malawi Demographic and Health Survey (MDHS), the
Malawi Micronutrient Survey (MNS) collected information on the
genetic burden of inherited blood disorders. Our objective was to
describe the prevalence and distribution of inherited blood disorders
among young children in Malawi and explore their associations with
malaria and anemia.
Methods
MDHS survey overview and sampling strategy
The Government of Malawi National Statistical Office and Commu-
nity Health Science Unit implemented the MDHS between October
2015 and February 2016. ICF International, the Centers for Disease
Control and Prevention, and Emory University provided technical
assistance for the MNS. The primary objective of the 2015-2016
MNS was to estimate the prevalence of anemia, micronutrient
deficiencies (iron, vitamin A), inflammation, infection (malaria, urinary
schistosomiasis), and inherited blood disorders (sickle cell trait/
disease, a-thalassemia trait, G6PD deficiency) in addition to measuring
growth and estimating the prevalence of undernutrition.46
The MDHS was a large, cross-sectional survey designed to provide
estimates for key demographic and health indicators for the country
as a whole, for urban and rural areas separately, and for each of the
28 districts in Malawi. The MNS was designed to produce national
and regional estimates of micronutrient status and other biomarkers.
From the 850 clusters included in the MDHS, 105 (35 per region:
North, Central, South) were randomly selected for the MNS. Within
clusters, households were randomly sampled (22 in rural clusters,
20 in urban clusters) and all children 6 to 59 months of age in the
household were invited to participate.
Ethical considerations
The National Health Sciences Research Committee in Malawi
granted ethical approval for the MDHS and MNS surveys, which
were designed to minimize participant risk. Community leaders granted
consent of survey activities. Caregivers gave consent for survey
participation of children 6 to 59 months of age. If clinically important
results were determined at the point of data collection (severe anemia,
positive malaria test, evidence of malnutrition, hematuria), the child was
referred to receive care at a local health center.
Survey administration and sample collection, storage,
and transport
The MDHS teams collected survey data electronically using tablet
computers; the MNS teams collected data on paper case report
forms that were translated to local languages. Upon arrival to each
cluster, the MNS team set up a mobile laboratory to facilitate
assessment of anthropometry and venous blood collection. Within
households that had consented to participate in the survey, children
aged 6 to 59 months were escorted to the mobile laboratory, where
informed consent was obtained from the caregivers. Length or
height and weight were measured using wooden length boards
(ShorrBoard, Weigh and Measure, LLC, Olney, MD) and elec-
tronic mother/infant scales (Seca GmbH & Co. KG, Hamburg,
Germany), respectively. Recumbent length was measured for
children ,24 months old; standing height was measured in
children 24 to 59 months old. Children had minimal clothing
(light fabric and diaper were acceptable) and were not wearing
shoes when weight was measured.
Whole blood was collected by venipuncture in an EDTA vacutainer
tube (Becton, Dickinson and Company, Franklin Lakes, NY), to test
for malaria using a rapid diagnostic test (SD BIOLINE Malaria
Plasmodium falciparum [HRP2], Alere, Inc., Waltham, MA) and to
measure hemoglobin concentration using the HemoCue 301
(Hemocue America, Brea, CA). Parents additionally provided self-
report of whether the child had malaria infection within the past
2 weeks. In addition, 100 mL of whole blood was spotted onto filter
paper and dried to create 2 dried blood spots (DBSs, Whatman
903 Protein Saver Cards, GE Healthcare, Pittsburgh, PA). One
DBS was used for hemoglobin electrophoresis to determine sickle
status locally and the second DBS was sent to the United States to
test for the presence of sickle cell disease or trait, a-thalassemia trait,
andG6PDdeficiency. Centrifuged serum, plasma, andDBS specimens
were maintained on a cold chain. Biomarkers of iron (ferritin), vitamin A
(retinol binding protein), and inflammation (C-reactive protein [CRP],
a-1-acid glycoprotein [AGP]) were measured in serum using sandwich
ELISA (VitMin Laboratory, Germany).47
Preparing DNA from DBS
Upon receipt at the Cincinnati Children’s Hospital Medical Center,
DBS samples were inventoried, DNA was extracted, and genotyp-
ing studies were performed. Two 3-mm punches were made from
each DBS to obtain genomic DNA following the InstaGene Matrix
protocol (BioRad, Hercules, CA) with the following modification;
65 mL of Instagene was used to bind DNA and only 50 mL was
collected following the final centrifugation step. All polymerase
chain reactions (PCRs) used 1 or 2 mL of DNA rich supernatant.
Determination of inherited blood disorders
Sickle cell status. Amplification of the b-globin gene was
performed using forward (59-TGC TTA CCA AGC TGTGAT TCC-3)
and reverse (59-CTT CCT ATG ACA TGA ACT TAA CCA-39)
primers. Hb S mutation (Glu6Val) was evaluated by a custom
TaqMan probe (RT-PCR) designed for the HbS (sickle, rs334)
polymorphism. For this reaction, 0.2 mL of PCR product was added
to 6 mL 2x Genotyping master mix, 0.6 mL 203 probe mix (Probe set
AHFA70S; forward 59- AGC AAC CTC AAA CAG ACA CCA T-39,
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reverse 59-CCC CAC AGG GCA GTA ACG-39, Vic 59-CTG ACT
CCT GAG GAG AA-39, FAM 59-CTG ACT CCT GTG GAG AA-39),
and water according to the manufacturers’ recommendation
(Applied Biosystems Foster City, CA). Figure 1A illustrates the
clear allelic discrimination of the 3 sickle genotypes: normal
hemoglobin (HbAA), sickle cell trait (HbAS), and sickle cell
disease (HbSS).
a-Thalassemia status. For the detection of a-thalassemia
trait (single or 2-gene deletions), the 3.7-kb a-globin gene deletion
(2a3.7) was scored using a copy-number variant TaqMan assay
with custom TaqMan probes, as previously described.48 Each
sample was amplified in triplicate to determine average relative
quantification (RQ) or copy number score. Each assay included
an internal coamplified control to assess the DNA quality. RQ values
corresponding to copy number variation cells were used as follows:
2 a-globin genes/2 a-globin gene deletions (2a3.7/2a3.7), 0.00 to
0.20; 3 a-globin genes/1 a-globin gene deletion (2a3.7/aa), 0.40
to 0.70; 4 a-globin genes/no a-globin gene deletions (aa/aa), 0.75
to 1.35; and 5 a-globin genes (a-globin gene triplication), 1.5 to 2.0.
Samples that fell outside of these defined ranges were repeated. In
the rare instance (,2% of samples) in which a single RQ value of the
triplicate was incongruous with the others, this value was eliminated
and not used in the final determination. A final a-thalassemia status
was not determined for 3 samples only (0.2% of total samples)
because of presumed poor DNA quality with poor amplification of
the internal coamplified control or copy number scores repeatedly
falling outside of the defined ranges. Controls for each experiment
included DNA from DBS samples with known a-thalassemia status;
additionally, a negative water control was included. Figure 1B
illustrates the distinction in amplification plots among the 4 possible
a-thalassemia results.
G6PD deficiency. The commonG6PDA2 variant was identified
using 3 commercially available TaqMan probe sets (Applied
Biosystems Foster City, CA); A376G (rs1050829) distinguished
A and B isoforms, G202A (rs1050828) identified the A2 variant, and
sex was scored using SRY_VIC and ABCD1_CCHS0H-FAM for
Y and X chromosomes, respectively. Each assay included positive
and negative controls, with random sample duplicates. Figure 1C
illustrates exemplary laboratory results for the 3 assays used to
determine G6PD status.
Local laboratory determination of sickle status
Hemoglobin electrophoresis was performed on the DBS as a local
diagnostic to supplement the molecular tests and develop further
capacity for a local sickle cell laboratory at Kamuzu Central Hospital
in Lilongwe, Malawi.49 The DBSwas cut in half and eluted in 100 mL
of hemolysate solution to extract hemoglobin before electrophore-
sis. Hemoglobin pattern was determined by hemoglobin electro-
phoresis using a Quickgel Chamber system and Titan Plus power
source (both from Helena Laboratories, Beaumont, TX). Hemoglo-
bin pattern was determined visually by inspecting for the presence
of normal and abnormal hemoglobin bands. Helena AFSC Control
was used as a marker for band identification.
Statistical analyses
All statistical analyses accounted for complex survey variables
(cluster, strata, weight) and were performed using SAS, version 9.4
(Cary, NC). Prevalence of genetic blood disorders were compared
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Figure 1. Molecular determination of sickle cell, a-thalassemia, and G6PD status. Each panel represents example allelic discrimination (A,C) or probe amplification (B)
plots for the reverse transcriptase-PCR assays used to determine each blood disorder. (A) Molecular determination of the presence of absence of the HbS mutation. (B) Probe
amplification plots by a-globin genotype, demonstrating later probe amplification with each a-globin gene deletion. (C) Allelic discrimination plot to determine G6PD A vs B
isoforms, the presence or absence of the A2 isoform, and a confirmatory sex assay to identify male and female samples.
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with malarial infection (as defined by rapid diagnostic test, binary
variable) and anemia severity (ordinal variable) using the Rao-Scott
modified x2 test. Genetic blood disorder prevalence and hemoglo-
bin concentration (continuous) were compared using generalized
estimating equations to account for correlation at the cluster level.
To assess patterns of anemia without an identifiable cause, a subset
of children with no evidence of malaria (by rapid test), inflammation
(CRP #5 mg/L. AGP #1 g/L), or iron deficiency as defined by a
normal inflammation-adjusted iron status (ferritin $12 mg/L) were
analyzed separately (n 5 300).
Ferritin was adjusted for inflammation using the Biomarkers
Reflecting Inflammation and Nutritional Determinants of Anemia
internal (country-specific) regression method, accounting for CRP
and AGP.50 Inflammation-adjusted iron deficiency was defined as
serum ferritin,12 mg/L. Anthropometry data were analyzed using
World Health Organization child growth standards to calculate
z scores.
Local prevalence of the HbS allele (HbAS or HbSS) in contrast to the
normal condition HbAA was mapped on the basis of a generalized
linear mixed model.51 Model parameters were estimated by maximum
likelihood, and prevalence was the mapped at the nodes of a 1-km2
grid across Malawi using the Prevmap package for the R platform.52
The prevalence predictions were then visualized using ArcGIS
(v10.3.1, ESRI, Redlands, CA). The generalized linear mixed model
were also fitted to the data on a-thalassemia and G6PD deficiency,
but in both cases the evidence for spatial correlation was very weak,
and so no attempt was made to map prevalence.
Results
Survey response rate and participant characteristics
The MNS was designed to target a sample size of 1500 preschool
children to detect a reduction in the prevalence of vitamin A
deficiency from 22% in 2009 to 15% in 2015-2016. A total of
1279 eligible participants were invited, 1233 (96%) agreed to
participate, and DBS were collected from 92.9% (1136/1223) of
children for genotyping studies. An additional 61 children were
excluded because they did not participate in venipuncture blood
draw, making inflammation and iron status unavailable, and 4 children
were missing hemoglobin data, which led to 1071 children included
in the final analysis. The dataset was a geographically representative
sample from the Northern (n 5 374), Central (n 5 408), and
Southern regions (n 5 289) of Malawi. Samples were collected
from 27 of the 28 districts of Malawi, with the only unrepresented
district being the exclave district of Likoma Island, located in Lake
Malawi. The mean age of participating children was 32.5 months;
gender was balanced, 30.9% were anemic, and 21.5% were iron
deficient (Table 1). The presence of any evidence of inflammation
(either elevated CRP or AGP) was common (56.6%) among children.
The prevalence of stunting and underweight was 35.1% and 18.4%,
respectively (Table 1).
Sickle cell status
HbAS was found in 105 children (weighted percentage, 9.1%)
(Table 2). Homozygous HbSS was found in only a single child. The
HbS allele frequency was 0.05. Children with a HbAA pattern did
not have a significantly higher prevalence of malaria (by positive
rapid diagnostic test), compared with children with HbAS (28.5%
vs 20.5%, P 5 .22). Geographically, HbAS was more prevalent in
the Central region (12.5%) than in the Northern (11.5%) and
Southern regions (3.8%) (data not shown). This distribution did not
align with the relative prevalence of malaria infection by rapid
diagnostic testing (Northern 5 20.6%, Central 5 30.9%, Southern
5 28.3%) or self-report of recent infection (Northern 5 20.4%,
Central 18.9%, Southern 5 26.1%).
Comparison of molecular and electrophoresis results
Molecular determination of sickle status was performed on 1137
samples; hemoglobin electrophoresis was performed on 1111
samples in separate locations. When comparing the 1108 samples
with results using both methods, there was excellent agreement
(k 5 0.86; 95% confidence interval, 0.82-0.91) with concordant
Table 1. Characteristics of children aged 6 to 59 mo, 2015-2016
Malawi MNS
Mean (95% CI) N
Male sex, % 51.3 (48.1-54.5) 530
Age, mo 32.5 (30.9-34.2) 1071
Region, %
North 13.7 (7.0-20.4) 374
Central 47.1 (33.5-60.6) 408
South 39.2 (26.1-52.3) 289
Rural residence 89.4 (78.3-100.0) 948
Wealth quintile, %
Lowest 26.8 (21.3-32.3) 249
Low 22.5 (18.9-26.1) 215
Middle 23.0 (18.9-27.0) 246
High 17.5 (14.1-21.0) 203
Highest 10.2 (5.1-15.2) 157
Household ITN use, % 66.2 (60.8-71.6) 739
Fever in last 24 h, % 11.9 (9.1-14.7) 136
Hb, g/dL 11.5 (11.4-11.6) 1071
Any anemia (Hb <11.0 g/L), % 30.9 (27.3-34.5) 335
Mild* 18.0 (15.3-20.6) 191
Moderate† 12.1 (9.0-15.2) 135
Severe‡ 0.9 (0.0-1.8) 9
Iron deficiency, %§ 21.5 (15.7-27.3) 207
Iron deficiency anemia, %§ 9.2 (6.1-12.4) 92
Vitamin A deficiency, %§ 3.7 (1.7-5.8) 39
(1) Malaria (rapid test), % 27.8 (20.2-35.4) 283
(1) Malaria (self-report last 2 wk), % 19.5 (14.8-24.2) 226
Any inflammation (CRP .5 mg/L; AGP .1 g/L), % 56.6 (51.6- 61.7) 604
Stunted (HAZ ,22), % 35.1 (31.0-39.1) 355
Wasted (WHZ ,22), % 4.3 (2.8-5.9) 41
Underweight (WAZ ,22), % 18.4 (14.6-22.3) 155
Data are weighted to account for survey design.
CI, confidence interval; ITN, insecticide-treated nets; HAZ, height-for-age z score; WAZ,
weight-for-age z score; WHZ, weight-for-height z score.
*Hb 10.0-10.9 g/L.
†Hb 7.0-9.9 g/L.
‡Hb ,7.0 g/L.
§Iron deficiency defined as inflammation-adjusted ferritin ,12 mg/L; iron deficiency
anemia defined as intraindividual anemia (Hb ,11 g/L) and iron deficiency; vitamin A
deficiency defined as retinol binding protein ,0.46 mmol/L.
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results for 1080/1108 (97.5%) of samples. There were 20 samples
called HbAA by the molecular technique but called HbAS by
hemoglobin electrophoresis, and 8 samples called HbAS by
molecular techniques but called HbAA by hemoglobin electropho-
resis. The 1 child with presumed HbSS was diagnosed by both
methods. The sensitivity and specificity of the electrophoresis
technique for the detection of HbS (including both HbAS and
HbSS) was 93% and 98%, respectively.
a-Thalassemia status
a-Thalassemia was the most common inherited blood disorder
detected. More than 2 of 5 children had either 1 (33.1%) or
2 (10.0%) a-globin gene deletions, consistent with the diagnosis
of a-thalassemia trait. Consistent with the frequency of the trans-
type a-thalassemia deletion in sub-Saharan Africa (2a3.7), there
were no samples with 3 a-globin gene deletions. Two gene
deletion a-thalassemia (2a3.7/2a3.7) was more common in the
Southern region (13.6%) than the Central (8.3%) or Northern
(5.1%) region (P 5 .008) (data not shown). Each gene deletion
was associated with a decrease in hemoglobin concentration that
was seen for children with and without evidence of malaria
infection (Table 3). Children without any deletions (aa/aa) had
significantly higher mean hemoglobin concentrations than those
with 1 (2a3.7/aa) or 2 (2a3.7/2a3.7) gene deletions (11.5 vs
11.3 and 10.9 g/dL, respectively; P , .001). The prevalence of
malaria diagnosed by rapid diagnostic test or by maternal self-
report did not differ by a-thalassemia status (Table 2).
We performed a subgroup analysis excluding children with notable
causes of anemia (malaria, inflammation, or iron deficiency) to assess
patterns of residual anemia (n 5 300). The association between
a-thalassemia trait and anemia was evident in this subgroup. Children
with the normal aa/aa genotype had a significantly higher (P , .01)
mean hemoglobin concentration (12.4 g/dL) and lower prevalence of
anemia (5.6%) than children with 1 (Hb 5 11.8 g/dL, 9.4%
prevalence of anemia) or 2 (Hb5 11.0 g/dL, 67.5% prevalence of
anemia) a-globin gene deletions (Table 4).
G6PD status
G6PD deficiency was also commonly found, with 20% of boys found
to be affected by hemizygotes and 34% of females found to be
heterozygous carriers of the A2 variant. The allele frequency for the
A2 variant was 0.20. There was a trend demonstrating decreased
prevalence of malaria for both boys with G6PD deficiency (26.9%
prevalence of malaria) and girls with G6PD trait (22.5% prevalence
of malaria) compared with unaffected boys and girls (31.4% and
26.5% prevalence of malaria, respectively; P . .05, Table 2).
There was a statistically significant difference in the hemoglobin
concentration for boys with G6PD deficiency when analyzed
according to recent malaria infection. Boys with G6PD deficiency
and a positive malaria test had a significantly higher hemoglobin
concentration (Hb 5 11.0 g/dL) than boys without G6PD
deficiency and a positive rapid malaria test (Hb 5 10.4 g/dL),
suggesting a possible protective effect of G6PD deficiency
(P 5 .02). There was a similar trend toward protection against
anemia for girls with G6PD deficiency or trait, but this was not
statistically significant (P 5 .08).
Overlapping blood disorders: prevalence,
distribution, and protection against malaria
Of the 1068 samples with results for all 3 inherited blood disorders,
650 (60.9%) had at least 1 abnormal result; 15 children were carriers
of all 3 blood disorders. The study did not demonstrate any increased
or decreased prevalence in malaria for children inheriting .1 blood
disorder.
Table 2. Prevalence of malaria and anemia severity by blood disorder among children 6 to 59 mo, Malawi 2016 (n 5 1071)
Blood disorder
Anemia
Overall prevalence(1) Malaria None Mild Moderate or severe
Sickle cell status, % (95% CI)
Normal 28.5 (20.5-36.5) 69.0 (64.9-73.0) 18.0 (15.2-20.8) 13.0 (9.6-16.5) 90.9 (87.9-93.9)
Sickle cell trait 20.5 (7.6-33.4) 70.3 (59.4-81.3) 17.4 (7.8-26.9) 12.3 (2.5-22.1) 9.1 (6.1-12.0)
Sickle cell anemia — — — 100 (100-100) 0.04 (0.0-0.1)
a-Thalassemia genotype, % (95% CI)
aa/aa 29.5 (21.3-37.7) 72.2 (67.7-76.7)* 15.1 (11.8, 18.3)* 12.8 (9.5-16.0)* 56.9 (51.4-62.3)
2a3.7/aa 26.0 (17.1-34.8) 70.2 (64.2-76.3)* 16.2 (11.0, 21.4)* 13.6 (4.2-22.5)* 33.1 (28.4-37.9)
2a3.7/2a3.7 26.5 (14.5-38.5) 44.7 (31.1-58.2)* 42.0 (26.8-57.1)* 13.3 (4.2-22.5)* 10.0 (7.7-12.2)
G6PD genotype: males, % (95% CI)
Normal 31.4 (23.2-39.6) 64.8 (59.4-70.1) 18.8 (14.4-23.3) 16.4 (11.8-20.9) 79.8 (75.0-84.6)
G6PD deficient 26.9 (9.4-44.4) 75.5 (65.1-86.0) 13.3 (6.4-20.2) 11.2 (3.9-18.4) 20.2 (15.4-25.0)
G6PD genotype: females, % (95% CI)
Normal 26.5 (19.6-33.4) 68.0 (63.3-76.7) 18.0 (13.1-23.2) 13.1 (7.3-16.4) 62.8 (57.8-67.9)
Carriers 22.5 (10.5-34.6) 72.4 (64.4-80.5) 18.2 (10.3-26.0) 9.4 (3.9-14.9) 34.6 (30.0-39.2)
G6PD deficient 33.4 (0.0-70.8) 77.2 (53.0-100.0) 19.6 (0.0-42.2) 3.2 (0.0-9.8) 2.6 (0.8-4.4)
Overall, % (95% CI) 27.8 (20.2-35.4) 69.1 (65.5-72.7) 18.0 (15.3-20.6) 13.0 (9.8-16.2)
Data are weighted to account for complex survey design. Malaria determined by rapid diagnostic test.
—, no observations.
*Distribution of anemia severity differs by a-thalassemia genotype (P 5 .0003) using the Rao-Scott modified x2 test.
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Geospatial distribution of inherited blood disorders
Samples were collected from children across all districts of Malawi.
There was an increased prevalence of sickle cell trait and a
decreased prevalence of G6PD deficiency in the Central compared
with the Northern and Southern regions. The prevalence of
a-thalassemia trait was highest in the Northern region and lowest
in the Southern region. Figure 2 demonstrates geospatial distribution
of the HbS allele with specific regions of Malawi suspected to have
higher prevalence of HbS than others.
Discussion
Anemia is common in the limited resource settings of sub-Saharan
Africa, including Malawi.34,44 It is typical for mild to moderate
anemia to be considered commonplace without extensive efforts
made to investigate the causes, clinical implications, or potential
treatment options. As with fever, malaria is often assumed to be the
primary cause of anemia by local providers, although this is certainly
not always the case. Nutritional (primarily iron deficiency) and
infectious etiologies (HIV, intestinal parasites) are the most widely
recognized global causes of anemia,34-42 but these data demon-
strate that inherited hematologic disorders are also common across
Malawi, likely playing an important role in the distribution and
severity of both anemia and malaria. Although only 1 child in the
cohort was found to have sickle cell disease, this study documented
that nearly 10% of children carry sickle cell trait. Given that there are
no screening programs and most persons of childbearing age are
not aware of their sickle status, each birth (assuming randommating
across the country) would have an ;0.83% chance of being at risk
for having a child with sickle cell disease (9.1% 3 9.1%). Because
this is a recessive disorder, each child at risk has a 25% risk of sickle
cell disease (ie, 0.207% of births). With a reported 638 900 births
per year and an assumption of randommating,53 an estimated 1323
children are born in Malawi each year with sickle cell disease. These
Table 4. Residual anemia and mean Hb by thalassemia, Malawi 2016 (n 5 300)
Anemia, % Normal (aa/aa) (n 5 178) Heterozygote (2a/aa) (n 5 97) Homozygote (2a/2a) (n 5 25) P
None (Hb $11.0 g/L) 94.4 (90.7-98.1) 90.6 (82.4-98.7) 32.5 (2.2-62.9) .0001
Mild (Hb 10.0-10.9 g/L) 4.8 (1.8-1.3) 7.4 (3.6-0.2) 66.2 (35.7-96.7)
Moderate or severe (Hb ,10.0 g/L) 0.8 (0.0-2.2) 2.1 (0.0-4.9) 1.3 (0.0-3.9)
Mean Hb (g/L) 12.4 (12.2-12.5) 11.8 (11.4-12.2) 11.0 (10.7-11.3) ,.0001
Restricted to children with no inflammation, iron deficiency, or malaria (inflammation defined as CRP #5 mg/L and AGP #1 g/L; iron deficiency defined as inflammation-adjusted ferritin
$12 mg/L; and malaria tested by rapid diagnostic test). Proportions compared using Rao-Scott modified x2 test; mean concentrations compared using linear regression with generalized
estimating equations to account for complex survey design.
Table 3. Mean Hb concentrations according to blood disorder stratified by malaria among children 6 to 59 mo, Malawi 2016
Blood disorder Prevalence, %
Mean Hb, g/dL*
Difference in Hb, g/dL†(2) Malaria (1) Malaria
Sickle cell status
Normal 90.9 11.7 (11.6-11.9) 10.5 (10.2-10.8) 21.2
Sickle cell trait 9.1 11.7 (11.4-12.0) 10.7 (10.1-11.4) 21.1
Sickle cell anemia ,0.1 6.7 — —
P .84 .47 .45
a-thalassemia genotype
Normal (aa/aa) 56.9 11.9 (11.7-12.0) 10.7 (10.3-11.0) 21.2
Heterozygous (2a3.7/aa) 33.1 11.6 (11.4-11.9) 10.5 (10.0-11.0) 21.3
Homozygous (2a3.7/2a3.7) 10.0 11.0 (10.7-11.3) 10.3 (9.7-10.8) 20.7
P ,.0001 .28 .10
G6PD genotype: males
Normal 79.1 11.7 (11.5-11.8) 10.4 (10.2-10.7) 21.3
G6PD deficient 19.6 11.3 (10.8-11.8) 11.0 (10.5-11.6) 20.3
P .56 .12 .02
G6PD genotype: females
Normal 63.3 11.8 (11.7-12.0) 10.2 (9.6-10.9) 21.6
Carriers 33.7 11.8 (11.6-12.1) 11.0 (10.2-11.9) 20.8
G6PD deficient 3.0 11.5 (11.0-12.0) 11.2 (9.1-13.3) 20.3
P .14 .045 .08
All estimates account for cluster, strata, and weighting; malaria stratification by rapid diagnostic test result.
*Difference in mean Hb by genotype modeled using linear regression with generalized estimating equations.
†Interaction P value signifies if there is a difference in mean Hb across malaria status between genotypes.
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calculations are meant to be estimates and, given the survival
advantage of sickle cell trait, there may be an even higher (than
9.1%) prevalence of sickle cell trait among adults of childbearing
age. Without available early diagnosis or intervention, it is likely that
many of these children born with sickle cell disease will die before
the age of 5 years.26 Malawi was successful in accomplishing
Millennium Development Goal 4 by reducing under-5 mortality
from 189 per 1000 live births in 1990 to 71 in 2013,54 but still
has room for improvement. To achieve the Sustainable Millennium
Development Goal of eliminating all preventable deaths and reducing
under-5 mortality to below 25 per 1000 live births, more attention to
sickle cell disease, through facilitation of early diagnosis and access to
important preventive care, will be an important step.
G6PD deficiency, although usually not associated with chronic
anemia, is an important comorbidity that can lead to acute
episodes of hemolysis triggered by infections or certain medica-
tions. Most notably, acute and severe hemolytic anemia can be
triggered in G6PD deficiency through the use of common antibiotics
and antimalarial medications, most notably sulfa antibiotics and
primaquine.55-57 A study investigating anemia in Malawian children
found G6PD to be among the few factors significantly associated
with severe anemia.44 G6PD is also a well-described risk factor for
severe neonatal hyperbilirubinemia, another important and treatable
global health problem.58 Approximately 1 in 5 boys in Malawi are
G6PD deficient and therefore at risk for both neonatal jaundice and
severe hemolytic anemia if exposed to certain antimalarial or antibiotic
medications. TheWorld Health Organization has advocated for point-
of-care G6PD testing to allow for the safe and appropriate use
of antimalarial medications, with a number of point-of-care assays
recently reported.59-62 It is thus important for health care providers
and administrators in Malawi to be cognizant of the high prevalence
of G6PD deficiency.
a-Thalassemia trait was common, affecting .40% of children;
those with 2 gene deletions were significantly more likely to have
anemia than those with 0 or 1 gene deletions. a-Thalassemia on its
own commonly results in mild anemia, but in settings with additional
risk factors for anemia, a-thalassemia status may result in more
profound anemia from other causes. a-Thalassemia is also especially
important to recognize in settings where iron deficiency is common
because the 2 are often confused with each another resulting from
the common laboratory finding of mild microcytic anemia. Knowing
a child’s a-thalassemia status is an important consideration when
evaluating and managing iron deficiency anemia. Although the data
from this study did not support the protective effect of a-thalassemia
trait against malaria or the potential negative epistasis when
a-thalassemia and sickle cell trait are inherited together, a number
of prior reports support these hypotheses.16-18,63
In addition to demonstrating the burden of inherited causes of
anemia in this population, this study also importantly demonstrated
the feasibility of using DBS to perform surveillance studies of these
inherited blood disorders, which are common across sub-Saharan
Africa. The frequencies and effect of these conditions are often not
well-recognized within the countries where they are so prevalent,
with most geographic epidemiologic data extrapolated from a
few small studies. DBS are commonly collected for a variety of
surveillance and diagnostic purposes and are often discarded after
only a small portion of the sample is used for the intended purpose.
In Uganda, DBS initially collected as part of an HIV surveillance
program were repurposed to be tested for sickle cell status and
resulted in the geospatial mapping of HbS across the country.64
Using the methods described here, similar strategies could be used
to demonstrate the prevalence and geographical distribution of
these important inherited hematologic disorders.
The study provides important novel data on the multifactorial
etiologies of anemia among young children in Malawi, but it is not
without limitations. The relatively small sample size may have under-
or overestimated the prevalence of these inherited blood disorders
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Figure 2. Geospatial distribution of HbS in Malawi. This map illustrates the
differences in the geospatial distribution of HbS, with areas in the Northeast and
West noted to have a higher prevalence of HbS than other areas of Malawi.
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in certain regions. The study did not attempt to exhaustively examine all
causes of anemia and notably did not test for the presence of intestinal
parasites or HIV. Of note, the 2009 Malawi MNS did test for the
presence of intestinal parasites and found a low prevalence and no
association with anemia.65 This could be the result of national
deworming campaigns targeting children aged 6 months to 5 years of
age. The diagnosis of malaria, primarily by rapid diagnostic test in this
study, has limitations, but was themost practical test in the field, where
microscopy was not available. The rapid test demonstrated a higher
prevalence of malaria than parental self-report (Table 1) and is likely a
more accurate measure of malaria infection, although not perfect.
In summary, this cross-sectional micronutrient study documents that
anemia, nutritional deficiencies, and inherited erythrocyte disorders
are common among young children in Malawi. It is important to
evaluate and manage each of these and to recognize that they may
occur simultaneously, with 1 condition often exacerbating another.
These data should be informative for health leaders and providers in
Malawi as they develop continued strategies to combat childhood
anemia and malnutrition. Finally, these methods may also be used in
other settings to document the burden of these important inherited
and acquired conditions.
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